Follow Bloomberg India on WhatsApp for exclusive content and analysis on what billionaires, businesses and markets are doing. Sign up here.

Global shipping is feeling the heat to cut emissions, and Japan’s just chalked up a big win in zero-emission technology. On September 8, 2025, ClassNK granted an Approval in Principle (AiP) to a ...

Most people know there are two types of diabetes—type 1 and type 2. Knowing which one you have matters quite a lot for how you treat them. But what you may not know about is a lesser-known variation ...

Medical Mysteries is a series that spotlights rare diseases or unusual conditions. Ryan Lim, 17, had a liver transplant in 2023 due to autoimmune hepatitis (AIH) diagnosed at age five. Post-transplant ...

A pizza shop with 30 delivery people ought to be able to deliver a lot of pizzas — if their cars don’t break down on the way. Likewise, genes that produce a lot of messenger RNA (mRNA) molecules can ...

O3R-5671 is designed to overcome the limitations of first-generation SIK inhibitors, providing a potential new oral treatment option for multiple autoimmune diseases Clinical Trial Application ...

Leuven, Belgium. September 4, 2025. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming patients’ lives with best-in-class medicines, today ...

Repository for reactive task and motion planning making use of active inference for symbolic planning, and a new multi-modal MPPI for motion planning. Rollouts are evaluated in IsaacGym, a ...

LA JOLLA, Calif., September 02, 2025--(BUSINESS WIRE)--Enlaza Therapeutics ("Enlaza" or the "Company"), the first covalent biologics platform company, today announced a multi-target drug discovery ...

Vertex Pharmaceuticals commits $45 million upfront to leverage Enlaza Therapeutics’ War-Lock platform to create drug conjugates and T cell engagers for autoimmune diseases and gentler conditioning for ...